Lentiviral vector can kill HIV-infected cells

NewsGuard 100/100 Score

Using a virus to kill a virus

In what represents an important step toward curing HIV, a USC scientist has created a virus that hunts down HIV-infected cells.

Dr. Pin Wang's lentiviral vector latches onto HIV-infected cells, flagging them with what is called "suicide gene therapy" - allowing drugs to later target and destroy them.

"If you deplete all of the HIV-infected cells, you can at least partially solve the problem," said Wang, chemical engineering professor with the USC Viterbi School of Engineering.

The process is analogous to the military practice of "buddy lasing" - that is, having a soldier on the ground illuminate a target with a laser to guide a precision bombing strike from an aircraft.

Like a precision bombing raid, the lentiviral vector approach to targeting HIV has the advantage of avoiding collateral damage, keeping cells that are not infected by HIV out of harm's way. Such accuracy has not been achieved by using drugs alone, Wang said.

So far, the lentiviral vector has only been tested in culture dishes and has resulted in the destruction of about 35 percent of existing HIV cells. While that may not sound like a large percentage, if this treatment were to be used in humans, it would likely be repeated several times to maximize effectiveness.

Among the next steps will be to test the procedure in mice. While this is an important breakthrough, it is not yet a cure, Wang said.

"This is an early stage of research, but certainly it is one of the options in that direction," he said.

Source: University of Southern California

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New report on HIV drug resistance: Challenges and recommendations